Antares Pharma, Inc. Common Stock (ATRS) Stock Quotes | Nasdaq Antares Pharma, Inc. Common Stock (ATRS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. ATRS Stock Price and Chart — EURONEXT:ATRS — TradingView View live ATRIUM EUR REALEST chart to track its stock's price action. Find market predictions, ATRS financials and market news. ATRS -- Is Its Stock Price A Worthy Investment? Learn More.
Mar 27, 2020 · Record Quarterly Revenue of $37.8 Million Earnings Per Share of $0.03 Record Annual Revenue of $123.9 Million, a 95% Increase over 2018 Annual Revenue Antares Pharma, Inc. (ATRS) today reported operating and financial results for the fourth quarter and full year ended December 31, 2019.
Home :: XYOSTED IMPORTANT SAFETY INFORMATION. What is the most important safety information I should know about XYOSTED? Blood Pressure Increases – XYOSTED can increase your blood pressure, which can increase your risk of having a heart attack or stroke and can increase your risk of death due to a heart attack or stroke. Your risk may be greater if you have already had a heart attack … Taking aim at Medicaid misclassifications like Mylan's ... Dec 05, 2018 · Mylan's Medicaid scrutiny was only part of its EpiPen scandal in 2016 and 2017. In the summer of 2016, the company came under fire for routine price hikes that made it difficult for consumers to
Find the latest Antares Pharma, Inc. (ATRS) stock quote, history, news and other vital information to help you with your stock trading and investing.
Share on Stocktwits. Antares Pharma (NASDAQ:ATRS) Earnings Information. Antares Pharma last released its earnings results on March 3rd, 2020. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, topping the consensus estimate of $0.00 by $0.03. The company had revenue of $37.84 million for the quarter ATRS Stock Price & Charts | Antares Pharma In depth view into ATRS (Antares Pharma) stock including the latest price, news, dividend history, earnings information and financials. ATRS Price Target and Analyst Ratings (Antares Pharma) 2 Wall Street analysts have issued ratings and price targets for Antares Pharma in the last 12 months. Their average twelve-month price target is $5.50, suggesting that the stock has a possible upside of 171.60%. The high price target for ATRS is $6.00 and the low price target for ATRS … Antares Pharma announces FDA approval of generic EpiPen ...